search
Back to results

The Effect of Working at Home to Reduce Risk of Respiratory Infection

Primary Purpose

Respiratory Tract Infections, COVID-19

Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Home office
Office
Sponsored by
Norwegian Institute of Public Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Respiratory Tract Infections focused on measuring COVID-19, Infection control, Office from home, Social distancing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • Over 18 years old
  • Employee in a company/organisation that has agreed to let their employees take part
  • Willing and able to work form home for 4 weeks (most of the time)

Exclusion crieria:

- Unable to work from home

Sites / Locations

  • Norwegian Institute of Public HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Home office for first 4 weeks, and office for the last 4 weeks

Office for first 4 weeks, and home office for the last 4 weeks

Arm Description

Participants will work from home for first 4 weeks, and at the office for the last 4 weeks

Participants will work at the office for the first 4 weeks, and from home during the last 4 weeks

Outcomes

Primary Outcome Measures

Respiratory infection
The proportion of participants who report having had symptoms of respiratory disease

Secondary Outcome Measures

COVID-19
Proportion of participants who test positive for SARS-CoV-2 (based on both self-reported and registry data)
Absenteeism
Number of days of absence from work.
Secondary cases of respiratory infection
Number of secondary cases (transmission from participants in the study) or outbreaks (2 or more cases)
Work-satisfaction
Self-reported work-satisfaction (Question: To what extent were you able to carry out your work in a good way during the last week? 5-unit ordinal scale from Very little to Very much).
Work-life balance.
Perceived work-life balance (Question: To what extent has your work been at the expense of your own or other family members' free time?) Ordinal 5-unit scale from Very little to Very much.

Full Information

First Posted
March 7, 2022
Last Updated
March 25, 2022
Sponsor
Norwegian Institute of Public Health
Collaborators
The National Institute of Occupational Health, Norway
search

1. Study Identification

Unique Protocol Identification Number
NCT05298488
Brief Title
The Effect of Working at Home to Reduce Risk of Respiratory Infection
Official Title
The Effect of Working at Home Versus at the Office on Risk of Transmission of SARS-CoV-2 and Other Respiratory Agents. A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 14, 2022 (Actual)
Primary Completion Date
March 30, 2023 (Anticipated)
Study Completion Date
September 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Norwegian Institute of Public Health
Collaborators
The National Institute of Occupational Health, Norway

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The researchers will recruit volunteers from various organisations who are willing and able to be randomised to either working from home for 4 weeks followed by working in the office for 4 weeks, or vice versa. The goal is to assess whether working from home has an impact on the risk of symptoms of respiratory infection.
Detailed Description
Working in the office entails to various extent contact with colleagues, and for some it includes close contact to others when using public transport to and from work. This likely increases the risk of transmission and many workplaces along with health authorities have strongly advised employees to work from home as much as possible during the COVID-19 pandemic. On the other hand, most people are infected from other family members, and working from home increases exposure to other family members. There are few, if any trials on the effects of teleworking/home office on the risk of transmission of SARS-CoV-2 and other respiratory agents. Studies that have looked at associations between teleworking and COVID-19 have found a negative correlation. A systematic review from the National Institute of Occupational Health (STAMI) showed that workers working from home experienced higher work satisfaction and productivity, while also reporting negative effects on work-life balance, professional isolation and working outside core hours. Effects on health outcomes were mixed. The quality of the studies was generally judged as low. However, working at the office could mean increased exposure to transmission of SARS-CoV-2 and other respiratory agents. Thus, both interventions do pose potential benefits and harms for the participants. Working from home is a broadly applied intervention nationally and internationally during the COVID-19 pandemic. Establishing what effect this intervention has on actual spread of SARS-CoV-2 and other respiratory agents could hence provide valuable insight to national and local authorities and decision-makers. The researchers propose to conduct a trial to assess whether working at home impacts on employees' risk of respiratory infection and reduce the risk of work-related outbreaks. The aim is to reject the null hypothesis that working at home does not reduce the risk of respiratory infections or outbreaks among employees. The researchers plan to conduct the trial as a two-arm multi-period crossover superiority trial where the employees are allocated into two equally sized groups. If this eases the recruitment of firms, the cross-over structure will be dropped. The first and second arm will cross-over (change treatment) after four weeks. Week 1 and week 5 will be considered run-in periods for these arms, and the data collected these run-in weeks will not be used as outcome data in the statistical analysis. The plan is to recruit 3-5 large firms with over 2000 eligible participants. Firms located in Oslo and neighbouring municipalities will be included. These are the areas That are seeing the highest incidence rates of SARS-CoV-2 in the ongoing covid-19 pandemic in Norway. All consenting employees in the selected organizations are eligible to participate in the trial. The organizations can define in advance certain key personnel that cannot take part in the trial. The investigators will compare the following interventions: Participants will strive to be working from home every day. Participants can go to the office in order to complete tasks that cannot be completed from home. Participants will be working from the office most days, but at least three days a week.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Tract Infections, COVID-19
Keywords
COVID-19, Infection control, Office from home, Social distancing

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The participants will be allocated to either office from home for the first four weeks, followed by working at the office for four weeks, or vice versa.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Home office for first 4 weeks, and office for the last 4 weeks
Arm Type
Experimental
Arm Description
Participants will work from home for first 4 weeks, and at the office for the last 4 weeks
Arm Title
Office for first 4 weeks, and home office for the last 4 weeks
Arm Type
Active Comparator
Arm Description
Participants will work at the office for the first 4 weeks, and from home during the last 4 weeks
Intervention Type
Behavioral
Intervention Name(s)
Home office
Intervention Description
Working from home
Intervention Type
Behavioral
Intervention Name(s)
Office
Intervention Description
Working at the office
Primary Outcome Measure Information:
Title
Respiratory infection
Description
The proportion of participants who report having had symptoms of respiratory disease
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
COVID-19
Description
Proportion of participants who test positive for SARS-CoV-2 (based on both self-reported and registry data)
Time Frame
8 weeks
Title
Absenteeism
Description
Number of days of absence from work.
Time Frame
8 weeks
Title
Secondary cases of respiratory infection
Description
Number of secondary cases (transmission from participants in the study) or outbreaks (2 or more cases)
Time Frame
8 weeks
Title
Work-satisfaction
Description
Self-reported work-satisfaction (Question: To what extent were you able to carry out your work in a good way during the last week? 5-unit ordinal scale from Very little to Very much).
Time Frame
8 weeks
Title
Work-life balance.
Description
Perceived work-life balance (Question: To what extent has your work been at the expense of your own or other family members' free time?) Ordinal 5-unit scale from Very little to Very much.
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: Over 18 years old Employee in a company/organisation that has agreed to let their employees take part Willing and able to work form home for 4 weeks (most of the time) Exclusion crieria: - Unable to work from home
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Petter Elstrom, PhD
Phone
+47 91149202
Email
petter.elstrom@fhi.no
First Name & Middle Initial & Last Name or Official Title & Degree
Atle Fretheim, PhD
Email
atle.fretheim@fhi.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Atle Fretheim, PhD
Organizational Affiliation
Head of Centre for Epidemic Interventions Research (CEIR)
Official's Role
Study Director
Facility Information:
Facility Name
Norwegian Institute of Public Health
City
Oslo
ZIP/Postal Code
0213
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Petter Elstrom, PhD
Email
petter.elstrom@fhi.no
First Name & Middle Initial & Last Name & Degree
Ingeborg H Elgersma, MA
Email
ingeborgHess.Elgersma@fhi.no

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The intention is to enable sharing of an anonymised dataset with all interested parties.
IPD Sharing Time Frame
After reporting of the trial findings, estimated to June 2023.

Learn more about this trial

The Effect of Working at Home to Reduce Risk of Respiratory Infection

We'll reach out to this number within 24 hrs